Mechanism of Action of Liraglutide

Introduction

Liraglutide is a long-acting GLP‑1 receptor agonist, injected once daily. It’s used for type 2 diabetes mellitus (T2DM) and chronic weight management, and also approved for reducing cardiovascular risk in patients with T2DM and established heart disease. It mimics the effects of endogenous GLP‑1 to improve glycemic control and promote satiety.

---

Step-by-Step Mechanism of Action

1. GLP‑1 receptor activation
   Liraglutide binds to GLP‑1 receptors located on pancreatic β‑cells, α‑cells, the brain, and gastrointestinal tract.
2. Glucose-dependent insulin secretion
   When blood glucose levels are high, it enhances insulin release from β‑cells.
3. Glucagon suppression
   It reduces glucagon secretion from α‑cells in hyperglycemic states.
4. Delayed gastric emptying
   It slows gastric motility, reducing postprandial glucose spikes.
5. Appetite reduction and satiety
   It activates satiety centers in the hypothalamus, leading to decreased caloric intake and weight loss.
6. Cardiovascular protection
   It improves endothelial function, reduces inflammation, and lowers blood pressure—offering CV benefits in diabetic patients.

---

Pharmacokinetic Parameters

Parameter	Value
Route	Subcutaneous injection, once daily
Absorption	~55–65%
Time to Peak (Tmax)	8–12 hours
Protein Binding	~98–99%
Metabolism	Proteolysis into small peptides
Half-life	~13 hours
Excretion	Urine and feces

---

Clinical Uses

• Glycemic control in type 2 diabetes
• Chronic weight management in obesity/overweight
• Reduction in major adverse cardiovascular events (MACE) in T2DM with cardiovascular disease

---

Adverse Effects

• Gastrointestinal complaints: nausea, vomiting, diarrhea, constipation
• Rare: pancreatitis
• Slight increase in heart rate
• Injection-site reactions
• Not recommended in patients with personal/family history of medullary thyroid carcinoma or MEN2

---

Comparative Analysis

Agent	Duration	Dosing	Weight Impact	Cardiovascular Benefit
Liraglutide	Medium-acting	Daily	Moderate weight loss	Proven CV risk reduction
Semaglutide	Long-acting	Weekly	Larger weight loss	Robust CV benefits
Dulaglutide	Long-acting	Weekly	Moderate weight loss	CV protection

---

MCQs

1. Liraglutide acts primarily on which receptor?
   a) GIP b) GLP‑1 c) DPP‑4 d) SGLT2
   Answer: b) GLP‑1
2. It enhances insulin secretion that is:
   a) Glucose-independent b) Glucose-dependent c) Suppressed d) Unaffected
   Answer: b) Glucose-dependent
3. The effect on gastric emptying is:
   a) Accelerated b) Unchanged c) Delayed d) Inhibited only at night
   Answer: c) Delayed
4. A key cardiovascular benefit of liraglutide is:
   a) Increased LDL b) Improved endothelial function c) Elevated BP d) Pro-arrhythmic effect
   Answer: b) Improved endothelial function
5. Liraglutide is administered:
   a) Weekly injection b) Daily injection c) Oral tablet d) Daily infusion
   Answer: b) Daily injection
6. Protein binding of liraglutide is:
   a) 50% b) 75% c) ~98% d) 100%
   Answer: c) ~98%
7. Which patient should avoid liraglutide?
   a) History of medullary thyroid carcinoma b) T2DM without CV disease c) Overweight without diabetes d) T2DM with CKD
   Answer: a) History of medullary thyroid carcinoma
8. The half-life is approximately:
   a) 4 hours b) 13 hours c) 24 hours d) 7 days
   Answer: b) 13 hours
9. Liraglutide’s weight loss is due to:
   a) Increased basal metabolic rate b) Appetite reduction c) Increased fat absorption d) Renal glucose loss
   Answer: b) Appetite reduction
10. Compared to dulaglutide and semaglutide, liraglutide is:
    a) Daily dosing b) Oral c) Weekly dosing d) Injectable monthly
    Answer: a) Daily dosing

---

FAQs

1. How soon does liraglutide reduce blood sugar?
Improvement in glycemic control is typically seen within 1–2 weeks after starting treatment.

2. Does it cause hypoglycemia when used alone?
No—it has minimal hypoglycemia risk when not combined with insulin or insulin secretagogues.

3. Can liraglutide aid weight loss?
Yes—patients may lose 5–10% of body weight over several months.

4. Is liraglutide safe in patients with renal impairment?
Yes—no dose adjustment is needed in mild-to-moderate renal dysfunction.

5. How often is thyroid function monitored?
Routine monitoring is not required unless there is family or personal history of thyroid cancer.

---

References

• Goodman & Gilman’s The Pharmacological Basis of Therapeutics, 13th Edition
• KD Tripathi. Essentials of Medical Pharmacology, 8th Edition
• DrugBank: Liraglutide pharmacology summary
• StatPearls: GLP-1 Receptor Agonists
• PubMed review: Cardiovascular effects of liraglutide